Exousia Health

Exousia Health is a biotechnology company focused on developing novel small molecule therapeutics for metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The company's core technology centers on mitochondrial uncoupling, a mechanism that increases metabolic rate and energy expenditure by facilitating proton transport across the mitochondrial membrane. By targeting mitochondrial efficiency, Exousia Health aims to provide treatments that safely reduce adiposity and improve insulin sensitivity. Led by industry veterans with extensive experience in metabolic research, the company is advancing its lead candidates through pre-clinical development toward human clinical trials.